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Regulation of receptor activator of 
nuclear factor κB-ligand (RANKL)-induced 
osteoclast differentiation is of current interest 
in the development of antiresorptive agents. 
Osteoclasts are multinucleated cells that play 
a crucial role in bone resorption. In the 
present study, we investigated the effects of N-
methyl pyrrolidone (NMP) on the regulation 
of RANKL-induced osteoclastogenesis. NMP 
inhibited RANKL-induced tartrate-resistant 
acid phosphatase (TRAP) activity and the 
formation of TRAP-positive multinucleated 
cells (MNCs). The RANKL-induced 
expression of nuclear factor of activated T 
cells-c1 (NFATc1) and c-Fos, which are a key 
transcription factors for osteoclastogenesis, 
were also reduced by treatment with NMP. 
Furthermore, NMP induced disruption of the 
actin rings and decreased the mRNAs of 
Cathepsin K (catK) and Matrix 
metallopeptidase 9 (MMP9), both involved in 
bone resorption. Taken together, these results 
suggest that NMP inhibits osteoclast 
differentiation and attenuates bone 
resorption. Therefore, NMP could prove 
useful for the treatment of osteoporosis or 




Bone remodeling is a physiological process that 
involves the resorption and synthesis of bone by 
osteoclasts and osteoblasts, respectively (1,2). 
Osteoclasts are known to be formed by the fusion 
of hematopoietic cells of the monocyte-
macrophage lineage during the early stage of the 
differentiation process (3). This process consists 
of multiple steps, including differentiation of 
osteoclast precursors into mononuclear 
osteoclasts, fusion of mononuclear preosteoclasts 
into mature multinucleated osteoclasts and 
activation of osteoclasts to resorb bone (4-7). 
The terminal differentiation in this lineage is 
characterized by acquisition of mature 
phenotypic markers such as expression of 
tartrate-resistant acid phosphatase (TRAP), 
calcitonin receptor, matrix metalloproteinase 9, 
and cathepsin K, as well as morphological 
conversion into large multinucleated cells and 
the ability to form resorption lacunae on bone (8-
10). The essential signaling molecules for 
osteoclast differentiation include RANKL and 
M-CSF (macrophage colony-stimulating factor) 
in bone marrow-derived macrophage precursor 
cells (11,12). RANKL is a member of the tumor 
necrosis factor (TNF) superfamily that is 
expressed in osteoblasts. It interacts with the 
osteoclast cell surface receptor RANK, which in 
turn recruits TNFR-associated factors (TRAFs) 
and plays a crucial role in the osteoclast 
differentiation axis (13,14). The downstream 
intracellular signaling mediated by RANK in 
osteoclast progenitor cells includes TRAF6-
dependent activation of nuclear factor κB 
(NFκB) via the IκB kinase (IKK) complex and 
mitogen-activated protein kinases (MAPKs) such 
as extracellular signal-regulated kinase (ERK), 
p38 MAPK and c-Jun N-terminal kinase (JNK) 
(7,11,15). In addition, RANKL induces the key 
transcription factors for osteoclastogenesis, 
NFATc1 and c-Fos (9,16,17). Therefore, 
chemical or natural compounds that specifically 
inhibit these steps could be developed as 
antiresorptive drugs for the treatment of 
metabolic bone disorders characterized by 
excessive osteoclastic bone resorption.  
Recently we found that NMP is a 
bioactive drug, since it enhances bone 
regeneration in vivo in rabbit calvarial defect 
model (18). At the cellular level, the 
pharmaceutical effect of NMP was confirmed 
since NMP increased early and late markers for 
maturation of preosteoblasts and human bone 
marrow-derived stem cells in vitro (18).  
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In the present study, we investigated the effects 
of NMP on RANKL-induced osteoclast 
differentiation in vitro, and characterized the role 
of NMP in osteoclast differentiation. We provide 
the first evidence that NMP inhibits RANKL-
stimulated osteoclastogenesis by suppressing 
NFATc1 expression, and RANKL-induced 
osteoclasts function by disturbing actin rings 




Reagents and antibodies. Recombinant RANK 
Ligand was purchased from Invitrogen (Life 
Technologies). NFATc1 (H-110) and c-Fos (H-
125) polyclonal antibodies were obtained from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA). Polyclonal anti-ERK1/2, anti-pERK1/2 
were obtained from Cell signaling (Cell signaling 
Technology, MA, USA). Trans-AM AP-1/c-Fos 
transcription factor kit was from Active Motif 
(Rixensart, Belgium). RNA extraction kit 
(RNeasy kit) was from QIAGEN. The BCA kit 
for protein determination was from Pierce 
Chemical Co. (Rockford, IL). TRAP solution 
was from Sigma Chemical Co. (St. Louis, MO). 
All other chemicals were available from Sigma 
Chemical Co. 
 
Cell cultures. RAW264.7 cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% foetal bovine serum 
(FBS) and antibiotics (100 U/ml penicillin G and 
100 mg/ml streptomycin). The cultures were 
never allowed to become confluent. Incubations 
were performed at 37°C in 5% CO2 in 
humidified air. Bone Marrow-Derived 
Macrophages (BMMs) were isolated from long 
bones of 6-week-old mice and were maintained 
in α-minimal essential medium (α-MEM) 
containing 10% heat-inactivated FBS in the 
presence of M-CSF (100 ng/ml) as described in 
(19). To generate osteoclasts from BMMs, cells 
were plated in 24-well tissue culture plates and 
cultured in the presence of 25 ng/ml RANKL and 
25 ng/ml M-CSF. 
 
Cell viability and proliferation assay. Effect of 
different concentrations of NMP on RAW264.7 
cells proliferation / viability was analyzed using 
a non-radioactive WST-1 Cell Proliferation 
Assay kit (Roche Diagnostics) according to the 
manufacturer's instruction. 
 
Tartrate resistant acid phosphatase (TRAP) 
activity and TRAP-staining. RAW264.7 cells 
were plated into a 12-well culture dish (Corning, 
NY) with different concentrations of NMP in the 
presence of 25 ng/ml of RANKL. The medium 
and factors were replaced every 2 days. After 6 
days of culture, the medium was removed and 
the cell monolayer was gently washed twice with 
PBS. The cells were then lysed with 200 µl of 
0.1% Triton X-100. TRAP activity in cell lysate 
was determined using TRAP solution (sodium 
acetate 0.1M pH 5.8, ascorbic acid 1 mM, KCl 
0.15 M, disodium tartrate 10 mM and p-
nitrophenyl phosphate 10 mM). An aliquot of 
cell lysate was added to TRAP solution and 
subsequently incubated for 30 minutes at 37°C. 
The reaction was stopped with NaOH 0.3 N and 
absorbance was measured at 405 nm using a 
micro-plate reader (BioTek). Results, normalized 
to protein content, are expressed in percentage of 
the activity obtained in RANKL stimulated cells. 
TRAP histochemical staining of the cells was 
performed using a leukocyte acid phosphatase kit 
(Sigma-Aldrich). Cultured cells were fixed with 
formaldehyde for 5 min at room temperature, 
washed with PBS and air-dried. After TRAP-
staining, TRAP-positive multinucleated cells 
(more than 3 nuclei) were counted under phase-
contrast microscopy. 
 
Pit formation assay. RAW264.7 cells were 
placed on bone slices in 24-well plates. After 
preincubation for 6 h, the bone slices were 
transferred to 12-well plates (1 bone slice/well) 
and further cultured in the presence or absence of 
25 ng/ml RANKL and 5mM NMP. The medium 
was replaced with a fresh one every 2 days. After 
9 days of culture, cells were removed and pit 
area was visualized by toluidine blue staining 
and quantified by image analysis system. 
Resorption pits of representative cultures are 
shown.  
 
Actin ring formation assay. Actin rings of 
osteoclasts were detected by staining actin 
filaments with rhodamine-conjugated phalloidin. 
Osteoclasts were formed from RAW264.7 cell 
cultures in the presence of RANKL (25 ng/mL) 
and NMP (1, 5 and 10 mM). At the end of 
incubation, osteoclasts were stained with 
rhodamin-conjugated phalloidin for actin and 
DAPI for nucleus. The distribution of actin rings 
was visualized and detected under a fluorescence 
microscope.  
 
Quantitative Real-time RT-PCR. RNA from 
RAW264.7 cells was extracted using the RNeasy 
kit from Qiagen. The mRNA was reverse 
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transcribed into cDNA. The resultant cDNA was 
subjected to real-time PCR with gene-specific 
primers using iQ SYBR Green super-mix and 
iCycler real-time PCR machine (both from Bio-
Rad Laboratories) according to the 
manufacturer's instructions. The primer 
sequences are presented in table 1. 
 
Protein preparation and Western blot analysis. 
RAW264.7 cells treated with the different 
compounds were rapidly frozen in liquid 
nitrogen and stored at −80°C for further analysis. 
Cells were lysed as described in (20). Proteins 
were fractionated onto a 12% SDS 
polyacrylamide gel electrophoresis, transferred 
to Immobilon P membranes (Millipore, 
Switzerland), and immunoblotted with specific 
antibodies. Detection was performed using 
peroxidase-coupled secondary antibody, 
enhanced chemiluminescence reaction 
(Amersham ECL Western Blotting Detection 
Reagents, GE Healthcare Europe GmbH, 
Otelfingen, Switzerland), and visualization using 
autoradiography. Membranes that were reprobed 
had been stripped in stripping buffer (62.5 mM 
Tris-hydrochloric acid, pH 6.8, 2% (w/v) SDS, 
100 mM β-mercaptoethanol) according to the 
manufacturer's protocol (Millipore). 
 
Zymography. Equal volumes of conditioned 
medium were loaded onto a 10% SDS-PAGE gel 
containing 0.1% porcine gelatin (Sigma). After 
electrophoresis, the gels were washed twice for 
15 min each in 2.5% Triton X-100 and then 
incubated overnight at 37 °C in substrate buffer 
(50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2 and 
0.02% Brij 35). The gels were stained with 
Coomassie Blue R-250 (Sigma) for 1 h. The gels 
were de-stained briefly in 50% methanol, 10% 
acetic acid. Areas of gelatinolytic activity 
appeared cleared against the blue background of 
the blue-stained undigested gelatin. 
 
AP-1 activation analysis. To detect AP-1 
activation in RAW264.7 cells, we used ELISA-
based Trans-AM AP-1 transcription factor kit 
(Active Motif, Rixensart, Belgium). Cells were 
plated in Petri dishes for 48h. Cells were pre-
incubated 4h in serum-free fresh medium and 
stimulated for 30 minutes as indicated in the 
figure. Preparation of nuclear cell extract was 
done according to the manufacturer’s 
instructions. The active form of c-fos in nuclear 
extracts can be detected using an antibody 
specific for an epitope that is accessible only 
when the nuclear factor is activated and bound to 
its target DNA. By using an antibody directed 
against c-Fos, the AP-1 dimer bound to the 
oligonucleotide is detected. A secondary 
antibody conjugated to horseradish peroxidase 
provides colorimetric visualisation. Absorbance 
was determined with a microplate reader 
(SynergyHT, BioTek). 
 
Statistical analysis.  Experiments were carried 
out independently at least three times. Results are 
expressed as the mean ± SD and were compared 
by Student's t-test. Results were considered 
significantly different for p<0.05. 
 
RESULTS 
NMP suppressed RANKL-induced 
osteoclastogenesis. To clarify the effects of 
NMP on osteoclastogenesis, we used RAW264.7 
cells and bone marrow-derived macrophages 
(BMMs) (Figure 1). Cells were incubated with 
NMP in the presence of RANKL for RAW264.7 
cells (Figure 1a) or NMP in the presence of 
RANKL and M-CSF for BMMs cells (Figure 
1b) as indicated in the figure. In the absence of 
NMP, RAW264.7 cells differentiate into mature 
TRAP-positive multinucleated osteoclasts 
(MNCs), while NMP (5 and 10 mM) reduced the 
formation and numbers of TRAP-positive MNCs 
in a concentration-dependent manner (Figure 
1a). The number of MNCs was quantified 
microscopically. In the presence of NMP (5 
mM), the MNCs number induced by RANKL 
was reduced approximately by 50%, whereas 10 
mM NMP abolished completely the formation of 
MNCs. In BMMs cells, NMP appears to have the 
same effect (Figure 1b). Indeed, treatment of 
BMMs with RANKL + M-CSF induces the 
formation of TRAP (+) MNCs and increases 
TRAP acitivity. NMP treatment completely 
blocked this effect. To exclude the possibility 
that the inhibition was due to cytotoxicity of 
NMP, cell cytotoxicity/viability was analyzed 
using a non-radioactive WST-1 Assay (Figure 
2). NMP demonstrated no cytotoxic effects after 
24 and 72 hours treatment with the concentration 
which effectively inhibited osteoclast formation 
by 50% (5 mM). We next examined in more 
details the effect of NMP on TRAP activity 
induced by RANKL in RAW 264.7 cells (Figure 
3). We found that TRAP activity was 
significantly reduced in the cells treated with 
RANKL and NMP compared to the cells treated 
with RANKL alone (Figure 3a). Furthermore, 
NMP dramatically reduced the number of nuclei 
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per osteoclast suggesting that NMP could 
modulate the fusion process (Figure 3b).  
NMP inhibits bone resorption and actin ring 
formation. We further examined if NMP has an 
effect on the ability of mature osteoclasts to 
resorb bone. RAW264.7 cells were plated on 
bone slices and stimulated with RANKL in the 
presence or absence of NMP. RANKL-
stimulated cells formed a number of pits, 
suggesting that the bone resorption activity of 
RANKL-treated cells made them into 
functionally active state resembling osteoclasts 
(Figure 4). Treatment with 5 mM NMP 
significantly reduced the formation of resorption 
pits in numbers and in overall area as compared 
to treatment with RANKL alone. Bone 
resorption occurs within the sealing zone, which 
is formed by an actin ring structure. In order to 
investigate the effect of NMP on actin ring 
formation, immunofluorescence analysis was 
performed (Figure 5). The majority of RANKL 
treated cells revealed well-formed actin rings 
(Figure 5a). Cells treated with RANKL in the 
presence of 5 mM NMP displayed mainly 
disrupted actin rings (Figure 5b). As expected, 
cells treated with RANKL in the presence of 10 
mM NMP shows no actin rings compared to cells 
treated with RANKL alone. Wilson et al., (21) 
reported that osteoclasts displaying a full actin 
ring or disrupted actin rings with more than 50% 
intact were identified as active. Our results are in 
line with this observation since with 1mM NMP, 
concentration which is ineffectively inhibited 
osteoclast differentiation, the actin ring is not 
completely disrupted (Figure 5b). 
NMP suppressed RANKL-induced MMP-9 and 
Cathepsin K. The bone resorption-related 
enzymes MMP-9 and Cathepsin K, are highly 
expressed in osteoclastic cells and play an 
important role in skeletal remodelling (22,23). 
Therefore we investigated the effect of NMP on 
the expression of MMP-9 and Cathepsin K 
expression (Figure 6) in detail. First we evaluate 
MMP 9 activity by gelatine zymography (Figure 
6a).  RAW264.7 cells treated with RANKL 
showed a concentration-dependant increase in 
MMP-9 gelatinolytic activity. This gelatinolytic 
activity was significantly decreased by NMP 
treatment and was correlated with the 
suppression of osteoclast differentiation 
visualized when the same culture were stained 
for TRAP (data not shown). Figure 6b 
demonstrates that RANKL induced an increase 
in MMP-9 mRNA and only treatment with 10 
mM NMP was able to decrease the RANKL-
induced MMP-9 mRNA. Cathepsin K mRNA 
expression was also increased by RANKL 
treatment. In the presence of NMP (5 and 10 
mM), RANKL-induced Cathepsin K mRNA was 
significantly suppressed (Figure 6b) already at 
5mM NMP. 
 
NMP inhibits NFATc1 and c-Fos expression 
and decreases AP-1 activation. NFATc1, a 
member of the NFAT family of transcription 
factor, has been shown to be up-regulated after 
RANKL stimulation and is important for 
osteoclast differentiation (10,16). Therefore, we 
examined the effect of NMP on the expression of 
NFATc1 (Figure 7). The stimulation of 
RAW264.7 cells with RANKL induced a high 
level expression of NFATc1 mRNA (Figure 7a). 
The treatment with NMP (5 mM) significantly 
decreased RANKL-induced NFATc1 mRNA. 
RANKL-induced NFATc1 mRNA was 
completely blocked by 10 mM NMP treatment. 
As shown in Figure 7b, cellular protein 
expression was correlated with mRNA 
expression. Indeed, the RANKL-induced 
NFATc1 expression was significantly and 
concentration-dependently attenuated by NMP 
treatment. With 10 mM NMP, the expression of 
NFATc1 induced by RANKL becomes similar to 
untreated cells.  
It is well known that c-Fos, a transcription factor 
for AP-1 complex, is required for osteoclast 
differentiation. This factor has been shown to 
bind to NFATc1 promoter and to be important 
for its activation (17,24). As shown in figure 8a, 
c-Fos expression was increased by RANKL. 
NMP treatment (5mM) significantly decreases c-
Fos expression induced by RANKL. Next, we 
examined whether NMP could suppress AP-1 
activity by TransAM AP-1 assays (figure 8b). 
The results showed that the AP-1 transcriptional 
activity was increased when cells were exposed 
to RANKL, whereas NMP suppressed AP-1 
activity, suggesting that NMP can inhibit 
RANKL-induced AP-1 activation. The 
specificity of the assay was confirmed by using 
positive control and wild-type and mutant 
oligonucleotids (data not shown). 
 
NMP inhibits RANKL-induced ERK pathway 
activation. Growth factors that stimulate ERK 
may ultimately control the activity of c-Fos and 
AP-1 dependent transcription (25). Recently, it 
has been reported that macrophage inflammatory 
protein (MIP)-1α induces osteoclast formation by 
activating the MEK/ERK/c-Fos pathway (26), 
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and vitamin E inhibited RANKL-induced 
osteoclast differentiation from precursors by 
suppression of c-Fos expression, possibly 
through inhibiting ERK (27). To investigate the 
role of ERK, JNK and p38 pathways in the 
inhibitory effect of NMP, RAW264.7 cells were 
treated as indicated in figure 9a, and whole cell 
extract was subjected to western-blot using 
phospho-ERK pathway antibodies. RANKL 
treatment induces ERK1/2 phosphorylation, and 
the presence of NMP resulted in a decrease in 
ERK1/2 phosphorylation. We also examined 
signaling steps upstream and downstream of 
ERK1/2. As shown in figure 9a, NMP 
suppressed the RANKL-induced MEK1/2 
phosphorylation, but also the phosphorylation of 
two downstream targets of ERK1/2, p90RSK and 
MSK1. NMP reduced RANKL-induced ERK 
activation but not p38 and JNK, suggesting that 






The major modalities currently used in 
osteoporosis treatment primarily include estrogen 
replacement therapy along with bisphosphonates, 
selective estrogen receptor modulators (SERM), 
and calcitonin. However, such therapies are 
associated with adverse effects, including breast 
cancer, hypercalcemia, and hypertension (5,28-
32).  
In medicine, N-methyl pyrrolidone (NMP) has a 
long track record as a constituent in medical 
devices approved by the Food and Drug 
Administration and thus can be considered as a 
safe and biologically inactive small chemical. 
Recently, we revealed that NMP enhances BMP 
activity by increasing the kinase activity of the 
BMP receptor complex for Smad 1,5,8 and p38 
and could be employed as a potent drug for bone 
tissue regeneration and engineering (18). Bone 
remodeling is tightly regulated by two processes: 
bone formation and bone resorption. The balance 
between both processes is a key for maintaining 
bone density. In this study, we report that NMP, 
in addition to its role in bone formation, is also 
able to inhibit osteoclast differentiation in vitro, 
since NMP attenuates the formation of TRAP (+) 
MNCs from precursor cells stimulated with 
RANKL. Our results suggest that NMP inhibits 
MNCs formation, including fusion of the 
mononuclear precursor cells since it decreases 
the number of nuclei per MNCs. The number of 
nuclei per MNC should reflect the relative rate of 
fusion of mononuclear precursors to form 
MNCs. 
NFATc1 and c-Fos are crucial transcription 
factors in RANKL-induced osteoclastogenesis. 
The role of c-Fos transcription factor in 
osteoclastogenesis has been revealed by 
knockout experiments (33). C-Fos knockout 
mice exhibited serious osteopetrotic phenotype, 
due to the failure of osteoclast formation. In 
addition, previous reports demonstrated that 
NFATc1 was not induced by RANKL 
stimulation in osteoclasts lacking c-Fos. The 
importance of NFATc1 on osteoclastogenesis 
was supported by in vitro experiments where 
NFATc1 knockout mice-derived stem cells failed 
to differentiate into osteoclasts and where bone 
marrow-derived macrophage cells, when forced 
to express NFATc1, differentiated to osteoclasts 
even in the absence of RANKL (24,33). In our 
study, NMP significantly suppressed NFATc1 
up-regulation normally seen after RANKL 
treatment. Previous studies have shown that 
NFATc1, the master regulator of 
osteoclastogenesis, is regulated by AP-1 
complex. AP-1 is a dimeric transcription factor 
composed of members of Jun and Fos family 
proteins. AP-1 converts extracellular signals in 
bone and immune cells into changes in the 
expression of specific target genes, which 
harbour an AP-1 binding site(s) in their promoter 
or enhancer regions (34).  
Since c-Fos upregulation is needed for NFATc1 
induction, it is possible that the suppression of 
NFATc1 expression by NMP is the consequence 
of the down-regulation of c-Fos, with subsequent 
down-regulation of AP-1 activity and inhibition 
of osteoclast-specific gene expression normally 
required for efficient osteoclast differentiation 
and bone resorption. This finding is important 
since AP-1 transcription factor links 
inflammatory processes to the activation of 
signalling pathways in osteoclast and therefore 
can be considered an important contributor to 
inflammatory bone diseases. 
Active osteoclasts display characteristic 
membranes, including the ruffled border, 
attachment zone, and the basolateral secretory 
membrane. After attachment to bone, the ruffled 
border secretes enzymes and protons enabling 
the solubilization and digestion of the bone 
matrix. Rapid cytoskeletal reorganization is 
essential for osteoclast function and formation of 
the specialized membranes (21,35). The NMP 
treatment disrupted actin ring formation in 
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osteoclasts. More importantly, osteoclastic bone 
resorption was strongly inhibited by NMP. 
Moreover, NMP inhibited RANKL-induced 
MMP 9 and cathepsin K upregulation, both 
highly expressed in osteoclastic cells and playing 
an important role in skeletal remodeling. 
Recently, Wilson et al., (21)  reported that 
cathepsin K activity is required for the initial 
formation of actin rings and thus for the 
activation of the osteoclasts. Our results are in 
line with this observation since at 5 and 10 mM 
NMP, concentrations which effectively 
suppressed RANKL-induced cathepsin K mRNA 
production and inhibited osteoclast 
differentiation, the actin rings are completely 
disrupted. Together, our results indicate that 
NMP plays a critical role in osteoclastic bone 
resorption by regulating actin ring formation and 
decreasing bone resorption-related enzymes. 
MAPK signalling cascades regulate transcription 
by multiple mechanisms, including the 
phosphorylation and activation of transcription 
factors, coactivators, corepressors, and the basal 
transcriptional machinery. Activated ERK1/2 
and/or p90RSK have been shown to target c-Fos 
(36-38) as well as participate in the activation of 
NF-κB (39). In this study, we reported that NMP 
decrease RANKL-induced activation of ERK 
pathway, and this inhibition might significantly 
reduces the induction of c-Fos trancription factor 
and subsequently AP-1 activation by RANKL. 
In the present study, we demonstrated for the 
first time the inhibitory effect of NMP on 
osteoclast differentiation and function. NMP 
inhibits the RANKL-induced osteoclast 
differentiation and function. Accordingly, a 
model is proposed to explain the bioactivity of 
NMP (Figure 10). NMP might act as inhibitor of 
several key events. Particularly, NMP inhibits 
RANKL-induced ERK 42/44 phosphorylation 
which is important for c-Fos expression and AP-
1 activation. Thus, the expression of NFATc1, 
which is regulated by AP-1, is decreased by 
NMP treatment. NMP is also able to inhibit 
osteoclast function by disturbing actin ring 
formation and reducing MMP 9 and cathepsin K 
expression, both involved in bone digestion. 
Therefore, NMP inhibits osteoclast 
differentiation by modulating AP-1 and NFATc1 
transcription factors, and inhibits osteoclast 
function by reducing MMP-9 and Cathepsin K 
expression and by disrupting actin ring 
formation. 
Taken together, our results demonstrate that 
NMP has an inhibitory activity on both 
osteoclast differentiation and function through 
mechanisms involving inhibition of the RANKL-
induced AP-1 activation. But additional work is 
needed to further pinpoint the exact site(s) where 
NMP exerts its suppressive activity on 
osteoclasts. 
Molecules, like NMP that enhance bone 
regeneration on one hand and suppress osteoclast 
differentiation on the other hand may have great 
therapeutic value in treating osteoporosis and 
other bone erosive diseases such as rheumatoid 
arthritis or metastasis associated with bone loss. 
Our findings suggest that NMP may potentially 
be useful for the treatment of bone diseases 
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Figure 1. Effects of NMP on osteoclastogenesis. (a) RAW264.7 cells were seeded in 12-well culture 
plates and treated for 6 days with NMP, RANKL or NMP+RANKL as indicated in the figure. For the 
visualisation of TRAP-positive multinucleated cells (MNCs), the cells were fixed and stained for 
TRAP activity as described in Methods. Stained cells were photographed, and TRAP (+) MNCs 
containing three or more nuclei were counted as osteoclasts. Data are expressed as mean S.D. (n=3). 
(b) BMMs from three different mice were treated with NMP (5 mM) in the presence of M-CSF 
(25 ng/ml) and RANKL (25 ng/ml) for 4 days. After culturing, the cells were fixed and stained for 
TRAP. In parallel, TRAP activity was determined as described in Methods. Data are expressed as 




Figure 2. NMP had no cytotoxic effect on Raw 264.79 cells. Cells were seeded on a 96-well plate, 
treated for either 24h (a) or 72h (b) with different concentration of NMP, or treated with RANKL and 
NMP as indicated in the figure (c). Cell viability/cytotoxicity was measured using WST-1 reagent as 
described in Methods. The results were normalized to cells grown in DMEM alone (Ctl). Data are 




















Figure 3. NMP suppressed osteoclast differentiation and decreased the fusion process. (a) TRAP 
activity, (b) microscopic view of MNCs after TRAP staining. RAW264.7 cells were seeded on a 24-
well culture plate, treated with RANKL alone or with different concentration of NMP as indicated in 
the figure. After 6 days incubation, TRAP activity was measured as described in Methods. Data are 



















Figure 4. NMP inhibits RANKL-induced bone resorption. RAW264.7 cells were cultured on bone 
slices and treated as indicated on the figure. After 9 days of culture, cells were completely removed 
and the bone slices were stained with toluidine blue followed by photography (a). Histograms 




















Figure 5. NMP disrupted RANKL-induced actin rings formation. RAW 264.7 cells were differentiated 
into osteoclasts in the presence of RANKL alone or with RANKL and 1, 5 or 10 mM of NMP for 6 





Figure 6. NMP inhibits RANKL-induced MMP 9 and cathepsin K expression: (a) Representative 
gelatine zymography assay of MMP-9 activity in RAW264.7 cells. RAW264.7 cells were cultured in 
serum-free DMEM supplemented with SITE liquid media as indicated in the figure. After 48 hours 
stimulation aliquots from supernatants were used in zymography assay as described in Methods. (b 
and c): MMP 9 and cathepsin K mRNAs were determined by real-time PCR after 48h stimulation 
with RANKL or RANKL in the presence of NMP (as indicated in the figure). Data are expressed as 







Figure 7. NMP suppresses RANKL-induced NFATc1 expression. RAW264 cells were stimulated with 
RANKL alone or with RANKL and different concentrations of NMP as indicated in the figure (48 h 
for mRNA and 72 h for proteins). (a): total RNA was extracted and NFATc1 mRNA was determined 
by real-time PCR as indicated in Methods. Data are expressed as mean S.D. (n=3) from a 
representative experiment. (b): Whole cell were subjected to Western-blot analysis with antibody 












Figure 8. NMP inhibits RANKL-mediated,C-Fos expression and AP-1 activation. RAW264.7 cells 
were treated with RANKL or RANKL and NMP as described in the figure. (a) C-Fos protein level 
was analyzed by western-blot using c-Fos and actin antibodies as indicated in Methods. (b) Nuclear 
extracts from RAW264.7 cells were used to detect AP-1 activation using an ELISA-based method 
(Trans-AM AP-1, Active Motif, Rixensart, Belgium) as indicated in Methods. The specificity of the 
assay was monitored by using the K-562 (TPA stimulated) nuclear extract and free wild-type or 
mutated oligonucleotides according to the manufacturer's instructions. Data are expressed as mean 







Figure 9. NMP inhibits RANKL-induced ERK activation but not p38 and JNK activation. RAW264.7 
cells were stimulated as indicated in the figure and whole cell extracts were separated on SDS-PAGE, 
transferred to PVDF membranes, and probed sequentially with phospho-ERK1/2 pathway antibodies 
(a).  RAW264.7 cells were stimulated with RANKL or RANL in the presence of 10 mM of NMP for 
the indicated time points, and activities of p38 and JNK were examined by Western blot analysis using 










Figure 10. Schematic model for the osteoclastogenesis inhibitory function of NMP. RANKL induced 
the activation of ERK pathway. Inhibition of this pathway by NMP significantly reduces the induction 
of c-Fos trancription factor and subsequently AP-1 activation by RANKL. The blockade of AP-1 
transcription factor considerably decreases NFATc1 trancription factor expression leading to 
suppresses osteoclastogenic gene expression and subsequent osteoclast formation and function. 
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